Evidence map›Paper›PMID 35013556›Full record

ArticleNature cell biology2022

The ubiquitin-dependent ATPase p97 removes cytotoxic trapped PARP1 from chromatin.

Dragomir B Krastev, Shudong Li, Yilun Sun, Andrew J Wicks, Gwendoline Hoslett, Daniel Weekes, Luned M Badder, Eleanor G Knight, Rebecca Marlow, Mercedes Calvo Pardo and 9 more

Open access · hybridAbstract read
In one paragraph

Article in Nature cell biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers.

0numbers the graph read from it
0cells of the map it votes in
98citing papers in PubMed
15.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

98 citing papers in PubMed, 158 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Targeting ubiquitination in disease and therapy.Signal transduction and targeted therapy · 2025
    Review
  17. Review
  18. Review
  19. METTL10-Mediated PIAS3 Methylation Links Purine Metabolism to Gastric Cancer Progression.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  20. Article

38 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 6 institutions in 4 countries.

Dragomir B Krastev *The CRUK Gene Function Laboratory, London, UK.ORCID http://orcid.org/0000-0003-4298-7272
Shudong Li *MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK.
Yilun Sun *Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-6249-2704
Andrew J WicksThe CRUK Gene Function Laboratory, London, UK.ORCID http://orcid.org/0000-0002-9307-3262
Gwendoline HoslettMRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-0030-7761
Daniel WeekesBreast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Luned M BadderThe Breast Cancer Now Research Unit, King's College London, London, UK.
Eleanor G KnightBreast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Rebecca MarlowBreast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Mercedes Calvo PardoFunctional Proteomics Laboratory, The Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0002-3477-9695
Lu YuFunctional Proteomics Laboratory, The Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0001-8378-9112
Tanaji T TaleleDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY, USA.
Jiri BartekDanish Cancer Society Research Center, Copenhagen, Denmark.ORCID http://orcid.org/0000-0003-2013-7525
Jyoti S ChoudharyFunctional Proteomics Laboratory, The Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0003-0881-5477
Yves PommierDevelopmental Therapeutics Branch, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.
Stephen J PettittThe CRUK Gene Function Laboratory, London, UK. Stephen.Pettitt@icr.ac.uk.ORCID http://orcid.org/0000-0003-3313-3857
Andrew N J TuttBreast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK. Andrew.Tutt@icr.ac.uk.ORCID http://orcid.org/0000-0001-8715-2901
Kristijan RamadanMRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK. Kristijan.Ramadan@oncology.ox.ac.uk.ORCID http://orcid.org/0000-0001-5522-021X
Christopher J LordThe CRUK Gene Function Laboratory, London, UK. Chris.Lord@icr.ac.uk.ORCID http://orcid.org/0000-0002-3226-0515
Institute of Cancer Research · GBUniversity of Oxford · GBNational Cancer Institute · USKing's College London · GBScience for Life Laboratory · SESt. John's University · US

Funding

DNA Repair, Cell Cycle Checkpoints and Apoptosis as Targets for Anticancer DrugsZIABC006150 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI POMMIER, YVES · 2009 to 2025
$23.0M
PROTEIN-ASSOCIATED DNA BREAKS AS INDICATOR OF TOPOISOMERASE INHIBITIONZ01BC006150 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI POMMIER, YVES · 1996 to 2008
$1.5M
Development of PARP-Isoform Selective Inhibitory Chemical ProbesSC3GM131971 · NIGMS · ST. JOHN'S UNIVERSITY · PI TALELE, TANAJI T · 2019 to 2022
$492k
Breast Cancer Now 2017NOVPCC1084Cancer Research UK 24439Intramural NIH HHS Z01 BC006150Medical Research Council MC_PC_12001/1Medical Research Council MC_UU_00001/1Medical Research Council MR/X006409/1NIGMS NIH HHS SC3 GM131971
6 · The paper itself

Abstract

Poly (ADP-ribose) polymerase (PARP) inhibitors elicit antitumour activity in homologous recombination-defective cancers by trapping PARP1 in a chromatin-bound state. How cells process trapped PARP1 remains unclear. Using wild-type and a trapping-deficient PARP1 mutant combined with rapid immunoprecipitation mass spectrometry of endogenous proteins and Apex2 proximity labelling, we delineated mass spectrometry-based interactomes of trapped and non-trapped PARP1. These analyses identified an interaction between trapped PARP1 and the ubiquitin-regulated p97 ATPase/segregase. We found that following trapping, PARP1 is SUMOylated by PIAS4 and subsequently ubiquitylated by the SUMO-targeted E3 ubiquitin ligase RNF4, events that promote recruitment of p97 and removal of trapped PARP1 from chromatin. Small-molecule p97-complex inhibitors, including a metabolite of the clinically used drug disulfiram (CuET), prolonged PARP1 trapping and enhanced PARP inhibitor-induced cytotoxicity in homologous recombination-defective tumour cells and patient-derived tumour organoids. Together, these results suggest that p97 ATPase plays a key role in the processing of trapped PARP1 and the response of tumour cells to PARP inhibitors.

Indexed as

Cell Line, TumorChromatinDisulfiramHCT116 CellsHeLa CellsHumansMCF-7 CellsNeoplasmsNuclear ProteinsPoly-ADP-Ribose Binding ProteinsPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase InhibitorsProtein Inhibitors of Activated STATSumoylationTranscription FactorsUbiquitinationChromatinDisulfiramNuclear ProteinsPARP1 protein, humanPIAS4 protein, humanPoly-ADP-Ribose Binding ProteinsPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase InhibitorsProtein Inhibitors of Activated STATRNF4 protein, humanTranscription FactorsValosin Containing ProteinVCP protein, human

Identifiers

PMID35013556
PMCPMC8760077
OpenAlexW4220908091

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.